Neisseria lactamica antigens complexed with a novel cationic adjuvant

References

• WHO. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011; 86:521 - 39; PMID: 22128384
   PubMedGoogle Scholar
• Evans CM, Pratt CB, Matheson M, Vaughan TE, Findlow J, Borrow R, et al. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis.. Clin Infect Dis 2011; 52:70 - 7; http://dx.doi.org/10.1093/cid/ciq065; PMID: 21148522
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004; 72:5955 - 62; http://dx.doi.org/10.1128/IAI.72.10.5955-5962.2004; PMID: 15385499
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074 - 8; http://dx.doi.org/10.1016/0140-6736(92)93086-3; PMID: 1357461
   PubMed Web of Science ®Google Scholar
• Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE 3rd, et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 2010; 28:6970 - 6; http://dx.doi.org/10.1016/j.vaccine.2010.08.048; PMID: 20732470
   PubMed Web of Science ®Google Scholar
• Troncoso G, Sánchez S, Criado MT, Ferreirós CM. Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis.. FEMS Immunol Med Microbiol 2002; 34:9 - 15; http://dx.doi.org/10.1111/j.1574-695X.2002.tb00597.x; PMID: 12208601
   PubMed Web of Science ®Google Scholar
• Finney M, Vaughan T, Taylor S, Hudson MJ, Pratt C, Wheeler JX, et al. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin 2008; 4:23 - 30; http://dx.doi.org/10.4161/hv.4.1.4806; PMID: 17921703
   PubMed Web of Science ®Google Scholar
• Tunes CF, Ferraz AS, Scola MCG, De Gaspari EN. Intranasal Delivery of Whole Cells of Neisseria Species: Study of Cross - Reactive Antigens in Rabbits. The Open Vaccine Journal 2008; 1:13 - 21; http://dx.doi.org/10.2174/1875035400801010013
   Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al, V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. [Epub ahead of print] Lancet 2012; 379:617 - 24; http://dx.doi.org/10.1016/S0140-6736(11)61713-3; PMID: 22260988
   PubMed Web of Science ®Google Scholar
• McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, et al. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. Pediatr Infect Dis J 2012; 31:e15 - 23; http://dx.doi.org/10.1097/INF.0b013e31823e1e34; PMID: 22094636
   PubMed Web of Science ®Google Scholar
• Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, et al. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 2007; 14:830 - 8; http://dx.doi.org/10.1128/CVI.00039-07; PMID: 17494638
   PubMed Web of Science ®Google Scholar
• Welsch JA, Granoff D. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun 2004; 72:5903 - 9; http://dx.doi.org/10.1128/IAI.72.10.5903-5909.2004; PMID: 15385492
   PubMed Web of Science ®Google Scholar
• Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 2002; 70:584 - 90; http://dx.doi.org/10.1128/IAI.70.2.584-590.2002; PMID: 11796586
   PubMed Web of Science ®Google Scholar
• Harris SL, Finn A, Granoff DM. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect Immun 2003; 71:3402 - 8; http://dx.doi.org/10.1128/IAI.71.6.3402-3408.2003; PMID: 12761124
   PubMed Web of Science ®Google Scholar
• Devoe IW, Gilchrist JE. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 1973; 138:1156 - 67; http://dx.doi.org/10.1084/jem.138.5.1156; PMID: 4200775
   PubMed Web of Science ®Google Scholar
• Wang LY, Frasch CE. Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model. Infect Immun 1984; 46:408 - 14; PMID: 6437983
   PubMed Web of Science ®Google Scholar
• Carmona-Ribeiro AM. Bilayer vesicles and liposomes as interface agents. Chem Soc Ver 2001; 30:241 - 7
   Web of Science ®Google Scholar
• Carmona-Ribeiro AM, Castuma CE, Sesso A, Schreier S. Bilayer structure and stability in dihexadecyl phosphate dispersions. J Phys Chem 1991; 95:5361 - 6; http://dx.doi.org/10.1021/j100166a080
   Web of Science ®Google Scholar
• Kano K, Romero A, Djermouni B, Ache H, Fendler JH. Characterization of surfactant vesicle as a membrane mimetic agent. 2. temperature-dependant changes of turbidity, viscosity, fluorescence polarization of 2 methylantracene, and positron annihilation in sonicated dioctadecyldimethylammoniun chloride. J Am Chem Soc 1979; 101:4030 - 7; http://dx.doi.org/10.1021/ja00509a002
   Web of Science ®Google Scholar
• Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718:22 - 31; http://dx.doi.org/10.1016/j.bbamem.2005.10.011; PMID: 16321607
   PubMed Web of Science ®Google Scholar
• Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 2006; 58:787 - 99; http://dx.doi.org/10.1211/jpp.58.6.0009; PMID: 16734980
   PubMed Web of Science ®Google Scholar
• Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121:216 - 26; http://dx.doi.org/10.1111/j.1365-2567.2007.02560.x; PMID: 17302734
   PubMed Web of Science ®Google Scholar
• Lincopan N, Espíndola NM, Vaz AJ, da Costa MH, Faquim-Mauro E, Carmona-Ribeiro AM. Novel immunoadjuvants based on cationic lipid: Preparation, characterization and activity in vivo. Vaccine 2009; 27:5760 - 71; http://dx.doi.org/10.1016/j.vaccine.2009.07.066; PMID: 19664738
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 1993; 90:4942 - 6; http://dx.doi.org/10.1073/pnas.90.11.4942; PMID: 8506338
   PubMed Web of Science ®Google Scholar
• Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 1996; 156:2809 - 18; PMID: 8609400
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97:811 - 6; http://dx.doi.org/10.1073/pnas.97.2.811; PMID: 10639162
   PubMed Web of Science ®Google Scholar
• Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. J Control Release 2001; 76:59 - 71; http://dx.doi.org/10.1016/S0168-3659(01)00412-6; PMID: 11532313
   PubMed Web of Science ®Google Scholar
• Pérez O, Batista-Duharte A, González E, Zayas C, Balboa J, Cuello M, et al. Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Braz J Med Biol Res 2012; 45:681 - 92; http://dx.doi.org/10.1590/S0100-879X2012007500067; PMID: 22527130
   PubMed Web of Science ®Google Scholar
• Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998; 5:479 - 85; PMID: 9665952
   PubMedGoogle Scholar
• De Gaspari E, Zollinger W. Expression of class 5 antigens by meningococcal strains obtained from patients in Brazil and evaluation of two new monoclonal antibodies. Braz J Infect Dis 2001; 5:143 - 53; http://dx.doi.org/10.1590/S1413-86702001000300007; PMID: 11506778
   PubMedGoogle Scholar
• Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997; 185:1173 - 83; http://dx.doi.org/10.1084/jem.185.7.1173; PMID: 9104804
   PubMed Web of Science ®Google Scholar
• Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res Immunol 1992; 143:494 - 503, discussion 574-6; http://dx.doi.org/10.1016/0923-2494(92)80060-X; PMID: 1439129
   PubMedGoogle Scholar
• Beveridge TJ. Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol 1999; 181:4725 - 33; PMID: 10438737
   PubMed Web of Science ®Google Scholar
• Mayrand D, Grenier D. Biological activities of outer membrane vesicles. Can J Microbiol 1989; 35:607 - 13; http://dx.doi.org/10.1139/m89-097; PMID: 2670152
   PubMed Web of Science ®Google Scholar
• Mashburn-Warren L, McLean RJ, Whiteley M. Gram-negative outer membrane vesicles: beyond the cell surface. Geobiology 2008; 6:214 - 9; http://dx.doi.org/10.1111/j.1472-4669.2008.00157.x; PMID: 18459967
   PubMed Web of Science ®Google Scholar
• Collins BS. Gram-negative outer membrane vesicles in vaccine development. Discov Med 2011; 12:7 - 15; PMID: 21794204
   PubMed Web of Science ®Google Scholar
• Lee EY, Choi DS, Kim KP, Gho YS. Proteomics in gram-negative bacterial outer membrane vesicles. Mass Spectrom Rev 2008; 27:535 - 55; http://dx.doi.org/10.1002/mas.20175; PMID: 18421767
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Høiby EA, Bjune G, Aase A, Halstensen A, Lehmann AK, et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand 1998; 92:323 - 33; PMID: 9554288
   PubMedGoogle Scholar
• Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 2004; 23:Suppl S285 - 92; PMID: 15597071
   PubMedGoogle Scholar
• Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21:734 - 7; http://dx.doi.org/10.1016/S0264-410X(02)00591-1; PMID: 12531351
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520 - 7; http://dx.doi.org/10.1001/jama.281.16.1520; PMID: 10227322
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Taylor S, Brookes C, Matheson M, Finney M, Kerr M, et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol 2009; 16:1113 - 20; http://dx.doi.org/10.1128/CVI.00118-09; PMID: 19553555
   PubMed Web of Science ®Google Scholar
• Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Feavers IM, et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002; 70:3621 - 6; http://dx.doi.org/10.1128/IAI.70.7.3621-3626.2002; PMID: 12065503
   PubMed Web of Science ®Google Scholar
• Gorringe AR. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?. Expert Rev Vaccines 2005; 4:373 - 9; http://dx.doi.org/10.1586/14760584.4.3.373; PMID: 16026250
   PubMed Web of Science ®Google Scholar
• Caputo A, Sparnacci K, Ensoli B, Tondelli L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr Drug Deliv 2008; 5:230 - 42; http://dx.doi.org/10.2174/156720108785914961; PMID: 18855591
   PubMedGoogle Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173:3148 - 54; PMID: 15322175
   PubMed Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006; 40:1 - 9; http://dx.doi.org/10.1016/j.ymeth.2006.05.016; PMID: 16997708
   PubMed Web of Science ®Google Scholar
• Lincopan N, Espíndola NM, Vaz AJ, Carmona-Ribeiro AM. Cationic supported lipid bilayers for antigen presentation. Int J Pharm 2007; 340:216 - 22; http://dx.doi.org/10.1016/j.ijpharm.2007.03.014; PMID: 17452086
   PubMed Web of Science ®Google Scholar
• Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res Immunol 1992; 143:494 - 503, discussion 574-6; http://dx.doi.org/10.1016/0923-2494(92)80060-X; PMID: 1439129
   PubMedGoogle Scholar
• Ito AY, Néri S, Machado MS, Tunes CF, De Gaspari EN. Homologous prime-boost strategy in neonate mice using Neisseria lactamica.. Vaccine 2009; 27:3422 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.01.114; PMID: 19460600
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248 - 54; http://dx.doi.org/10.1016/0003-2697(76)90527-3; PMID: 942051
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680 - 5; http://dx.doi.org/10.1038/227680a0; PMID: 5432063
   PubMed Web of Science ®Google Scholar
• Schales O, Schales SS. A simple and accurate method for the determination of chloride in biological fluids. J Biol Chem 1941; 140:879 - 84
   Google Scholar
• Grabowski E, Morrison I. Particle size distribution from analysis of quasi-elastic light scattering data. In: Dahneke, B. Measurements of Suspended Particles by Quasi-Elastic Light Scattering, New York: Wiley-Interscience; 1983, p. 199-236.
   Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350 - 4; http://dx.doi.org/10.1073/pnas.76.9.4350; PMID: 388439
   PubMed Web of Science ®Google Scholar